Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antithymocyte immunoglobulin
- Development stage
- Phase 4
- Lead developer
- Sanofi
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Antithymocyte immunoglobulin** is a polyclonal antibody preparation derived from either horse (equine) or rabbit immunization with human thymocytes. It functions as an immunosuppressive agent and is primarily indicated for the prophylaxis and treatment of acute rejection in organ transplantation (notably kidney) and for treatment of aplastic anemia and graft-versus-host disease (GVHD) following stem cell transplantation. The drug acts by binding to multiple surface antigens on human T-lymphocytes, leading to T-cell depletion through complement-mediated cytotoxicity or apoptosis. This suppresses the patient's immune response, reducing the risk of transplant rejection or autoimmune activity. The specific type (rabbit or equine) and brand may be chosen based on the clinical scenario and patient factors[1][2][3][4][5][6][8].
- Brand names
- AtgamThymoglobulin
- Other names
- antithymocyte globulinlymphocyte immune globulinanti-thymocyte globulinanti-thymocyte globulin [rabbit]anti-thymocyte globulin [equine]ATGAMThymoglobulin
02
Targets
ITGAL (Integrin alpha L (CD11a))ITGB2 (Complement receptor 4)CD1A (T-cell surface glycoprotein CD1a)CD2 (T-cell Surface Antigen CD2)IL2RA (Interleukin-2 receptor alpha subunit)CD3 (T-cell surface glycoprotein CD3)CD4 (T lymphocyte surface antigen)CD44 (CD44 antigen)PTPRC (Receptor-type tyrosine-protein phosphatase C)CD8A (CD8 alpha/beta Coreceptor)CD86 (T-lymphocyte activation antigen CD86)FCGR2B (Fc gamma receptor IIB)HLA class I heavy chainHLA-DR (Human leukocyte antigen DR)ITGAV (Integrin αV)ITGB1 (Integrin beta-1)ITGB3 (Integrin beta-3)
Beyond the preview
Go deeper on antithymocyte immunoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antithymocyte immunoglobulin.